Wednesday, September 17, 2025

European Investment Bank grants Fresenius €400 million for research, development, and capacity expansion

Healthcare group Fresenius has secured a €400 million loan from the European Investment Bank (EIB) to expand its research and development activities as well as production capacities in Europe. The investments will focus on innovative medical products and biosimilars, with the goal of improving access to modern and affordable healthcare in the EU.

The EIB-financed initiatives will strengthen pharmaceutical production in Europe and enhance supply security. This funding is part of the #FutureFresenius agenda, through which the company aims to secure long-term competitiveness.

“Our mission at Fresenius is to save and improve lives. Investments in our core business – including the development of innovative, affordable healthcare products – are a key part of Rejuvenate, the current phase of #FutureFresenius,” emphasized CFO Sara Hennicken.

The EIB also highlighted the strategic importance of the partnership: “Our long-standing cooperation with Fresenius underlines the EIB’s commitment to accessible, high-quality healthcare across Europe,” said Nicola Beer, Vice-President of the EIB.

According to an IQVIA study, generics account for around 70% of prescribed medicines in Europe, but only 20% of total drug costs. In the past five years alone, Fresenius has invested more than €1 billion in European production sites. With its “Local-for-Local” strategy, the company aims to supply European patients with medicines produced in Europe.

Over the last five years, the EIB itself has provided more than €22 billion in financing for the health and life sciences sector. It has been supporting Fresenius’ long-term innovation projects for about 20 years.

With this latest loan, both partners are laying the groundwork for a more resilient, innovative, and sustainable healthcare system in Europe.